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Forced lineage conversion of accessible cell types can supply scarce or inaccessible cells for research and
therapy. Two papers in Nature now report the identification of transcription factors sufficient for inducing
therapeutically effective hepatocyte function in fibroblasts (Huang et al., 2011; Sekiya and Suzuki, 2011).Hepatocytes are responsible for both
function and regeneration of the adult
liver. An unlimited source of human
hepatocytes would be of great value
for modeling and understanding liver
diseases, drug efficacy and toxicity
testing, and cell replacement therapy.
Because primary human hepatocytes
are scarce and, despite their ability to effi-
ciently proliferate in vivo, cannot be
expanded in vitro, much effort has been
focused on generating surrogate hepato-
cytes from pluripotent stem cells. For
this purpose, current protocols use
growth factors that have been identified
in studies of mouse liver development to
guide the formation of ventral endoderm
and subsequent differentiation steps that
produce liver progenitors and mature
hepatocytes (Si-Tayeb et al., 2010; Zaret
and Grompe, 2008). Now Huang et al.
and Sekiya et al. investigated whether
the transcription factors activated by
these growth factors can be used to
induce direct hepatocyte differentiation
of fibroblasts, a readily accessible, devel-
opmentally unrelated cell type.
Prompted by pioneering work on
reprogramming of fibroblasts to pluripo-
tency or neuronal, cardiac, or hematopoi-
etic differentiation (Chambers and Studer,
2011), both groups started by overex-
pressing in mouse fibroblasts a cohort of
transcription factors previously reported
to play a role in liver development and
hepatocyte function (Kyrmizi et al., 2006;
Zaret and Grompe, 2008). Then, using
de novo hepatocyte-specific gene ex-
pression as a marker for the formation
of induced hepatocyte-like (iHep) cells,
they gradually eliminated those factors
that were not essential for the reprogram-
ming process (Table 1).Remarkably, both groups found that the
number of factors needed to induce hepa-
tocyte differentiation in fibroblasts was
small: overexpression of a Forkhead box
A protein (Foxa), either alone or in combi-
nation with GATA-binding protein 4
(Gata4), was essential for iHep cell gener-
ation. This finding is not unexpected,
considering that during development
these so-called pioneer factors establish
competence for liver specification by
opening chromatin regions of liver-
specific genes for binding of transcrip-
tional activators (Si-Tayeb et al., 2010). In
addition to pioneer factors, iHep cell
generation required only a single tran-
scriptional activator, hepatocyte nuclear
factor 1a (Hnf1a) in the study by Huang
et al. and Hnf4a in the study by Sekiya
et al. iHep cells exhibitedmany character-
istics and functions of hepatocytes,
although generally at lower levels than
primary cells. Although both papers stress
the point that liver progenitor intermedi-
ates were not produced in the reprogram-
ming process, incomplete hepatocyte
differentiation and expression of certain
marker genesby iHepcells are compatible
with an immature or progenitor-like state
(Dorrell et al., 2011). Moreover, similar to
adult liver progenitors (Shin et al., 2011),
iHep cells efficiently proliferated in vitro.
In fact, in contrast to other examples of
direct reprogramming, proliferation may
be a prerequisite for reprogramming to
hepatocytes: Sekiya et al. observed that
iHep cells could be passaged many
more times than the embryonic fibro-
blasts from which they originated. Huang
et al. succeeded in generating viable
iHep cells only after inactivating the cell
cycle inhibitor p19Arf in their starting
fibroblast population. Furthermore, theyCell Stem Ceobserved increased iHep cell colony
formation after eliminating Hnf4a from
their reprogramming strategy. Hnf4a is
known to inhibit proliferation (Lazarevich
et al., 2004). However, it remains unclear
why overexpression of Hnf4a impaired
proliferation in the hands of Huang et al.,
but not Sekiya et al. The fact that Huang
et al. used adult fibroblasts, whereas
Sekiya et al. used embryonic fibroblasts,
is not likely the reason because Sekiya
et al. confirmed their findings in adult
cells. A possible explanation could be
that Hnf4a levels were higher in iHep cells
of Huang et al. because of the lentiviral
vector system they used and because
they overexpressed Hnf4a together with
Hnf1a, which activates the endogenous
Hnf4a promoter (Kyrmizi et al., 2006).
Along these lines, it would be interesting
to know whether the spontaneous prolif-
eration of iHep cells observed by Sekiya
et al. was also facilitated by p19Arf sup-
pression. p19Arf is suppressed by Tbx3
in embryonic liver progenitors (Suzuki
et al., 2008), and although Sekiya et al.
found that Tbx3 overexpression was
not essential for iHep cell generation,
it is possible that their reprogramming
strategy activated endogenous Tbx3.
Importantly, iHep cells were also
capable of proliferating in vivo: iHep
cells engrafted and expanded in livers
of fumarylacetoacetate hydrolase (Fah)-
deficient mice, a model of the human liver
disease tyrosinemia that develops liver
failure unless treated with the drug
NTBC (Dorrell et al., 2011). However, in
contrast to primary hepatocytes, which
repopulate virtually the entire Fah-defi-
cient liver within 8 weeks, iHep cells
showed variable repopulation efficiency
and failed to rescue all mice from death.ll 9, August 5, 2011 ª2011 Elsevier Inc. 89
Table 1. iHep Cell Generation and Characterization
Huang et al. Sekiya et al.
Cells TTF, MEF MEF, MDF, KUM10
Overexpression
systems
vectors lentivirus retrovirus
promoters EF1a MSCV LTR
Factorsa ventral endoderm Foxa1/2/3, Gata4 Foxa1/2/3, Gata4/6, Hnf1b
liver progenitor Hex, Hnf1a, Hnf6 Hex, Hnf1a, Hnf6, Tbx3
hepatocyte Coup-TF1, Fxr, Hlf, Hnf4a, Jarid2, Lrh1, Pxr C/epba, Hnf4a
proliferation and survival p19Arf inactivation spontaneous
conversion efficiency ? 0.3%
Differentiation
in vitro
liver progenitor
intermediate?
Afp, Krt19 gene expression Afp, Krt7, Krt19, Prom1, Sox9
gene expression
fibroblast differentiation some residual fibroblast-specific
gene expression
lack of the fibroblast-specific proteins
a-SMA and vimentin
hepatocyte differentiationb partial deficiency in hepatocyte-specific functions,
including lower albumin secretion and lower
or lacking CYP-dependent drug metabolism
partial deficiency in hepatocyte-specific
functions, including lower albumin secretion,
glucose release, triglyceride synthesis,
and CYP-dependent drug metabolism
Function in vivo intrasplenic injection 8 3 105 iHep cells per Fah- and
Rag2-deficient mouse
1 3 107 or 2 3 106 iHep cells per
Fah-deficient mouse
survival after NTBC
withdrawal
5/12 mice at 8 weeks
(TTF-injected controls dead by 6 weeks)
6/14 mice at 10 weeks
(MEF-injected controls dead by 4 weeks)
liver repopulation 5%–80% ?
normalization of plasma
liver disease markersb
tyrosine, bilirubin, ALT lowered
to 3-fold elevation
bilirubin and ALT lowered
to 3-fold elevation
Abbreviations: Afp, a-fetoprotein; ALT, alanine aminotransferase; a-SMA, a-smooth muscle actin; CYP, cytochrome P450; EF1a, human elongation
factor-1a; Krt7/19, keratin 7/19; KUM10, adult mouse bone marrow mesenchymal cells; LTR, long terminal repeat; MDF, adult mouse dermal fibro-
blasts; MEF, mouse embryonic fibroblasts; MSCV, murine stem cell virus; NTBC, 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione; Prom1,
Prominin 1; Sox9, Sry-box containing gene 9; TTF, adult mouse tail-tip fibroblasts.
a Factors categorized based on the stage of mouse liver development at which they predominantly function (Kyrmizi et al., 2006; Zaret and Grompe,
2008). Underline denotes factors essential for iHep cell generation. Strikethrough denotes factors inhibiting hepatic gene expression and/or epithelial
colony formation.
b Relative to primary mouse hepatocyte cultures or transplants.
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PreviewsMoreover, liver function was not com-
pletely normal in the survivors, and it is
currently unclear whether this was due
to insufficient liver repopulation, poten-
tially reflecting limited proliferation of
iHep cells in vivo, or due to impaired
functional output per iHep cell. However,
the findings that (1) up to 80% liver repo-
pulation with iHep cells was possible
and (2) iHep cells ceased to express liver
progenitor markers in vivo suggest that
current limitations can be overcome in
the future.
An obvious next step is to generate
iHep cells from human fibroblasts, which
appears feasible, considering that signals
identified in mouse liver development
can direct the differentiation of human
pluripotent stem cells into hepatocytes.
Provided that human iHep cells function
andproliferate similarly to themousecells,
they would be promising therapeutic90 Cell Stem Cell 9, August 5, 2011 ª2011 Elcandidates: correction of most human
liver diseases requires replacing billions
of hepatocytes. iHep cells may allow this
demand to be met because of their ability
to proliferate in vitro and in vivo, which
would facilitate producing and transplant-
ing a large cell mass that could further
expand in response to disease-intrinsic
or artificial stimuli, such as those elicited
by Fah deficiency or localized liver
irradiation (Yamanouchi et al., 2009). In
addition, iHep cell transplantation would
not carry the risk of teratoma formation
from contaminating pluripotent stem
cells, which has hampered the clinical
application of pluripotent stem cell-
derived hepatocytes. Importantly, the
finding by both Huang et al. and Sekiya
et al. that continued transgene expression
was not needed to maintain iHep cell
identity in vitro suggests that these cells
can be generated without viruses and,sevier Inc.thus, in a clinically acceptable fashion.
Clearly, iHep cells have great potential
for liver research and liver cell therapy.
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Bone morphogenic proteins (BMPs) act as inducers of diverse cellular fates in human embryonic stem cells,
but the mechanisms responsible remain poorly understood. In this issue of Cell Stem Cell, Bernardo et al.
(2011) demonstrate that different BMP-induced differentiation programs may be orchestrated by similar
key target genes.The first differentiation event in mamma-
lian development takes place at the mor-
ula stage, when the cells of the embryo
segregate into two major lineages: (1) the
inner cell mass, which will give rise to the
embryo proper, and (2) the surrounding
trophectoderm, which will form the em-
bryonic parts of the placenta. There are
key transcription factors involved in this
segregation process, such as NANOG,
which becomes restricted to the inner
cell mass, and CDX2, which is crucial for
establishing the trophoblast lineage (Stru-
mpf et al., 2005). After the two lineages
have formed, cells do not cross this
boundary at any later stage during de-
velopment. Accordingly, mouse embry-
onic stem cells (ESCs), which are de-
rived from the inner cell mass, do not
normally differentiate into trophoblasts
in vitro. Strikingly, however, the Thom-
son group reported that human ESCs
(hESCs), unlike mouse ESCs (mESCs),
are capable of differentiating into pla-
cental hormone-secreting syncytiotro-
phoblast-like cells following stimulation
with recombinant BMP4 (Xu et al., 2002),
a finding that has also been reproduced
by others.
It is now generally accepted that,
despite their blastocyst origin, hESCs
resemble postimplantation epiblasts, be-
cause they share a number of characteris-
tics with mouse epiblast stem cells thatare directly derived from this pluripotent
tissue. One such hallmark is strong re-
sponsiveness to BMP stimulation, and
BMP signaling is crucial for mesoderm
formation during gastrulation. Indeed, re-
combinant BMP addition is frequently
applied to inducemesodermal differentia-
tion in hESCs (Murry and Keller, 2008).
BMP responsiveness and overall simi-
larity to epiblast tissue, however, still do
not provide a straightforward explana-
tion for why hESCs would also generate
trophoblast in response to BMP, because
the in vivo epiblast does not do that either.
In a comprehensive study in this issue of
Cell Stem Cell, Bernardo et al. (2011)
now address how different cellular fates
are induced by BMP in hESCs. Together
with independent results by Yu et al.
(2011), the data shed new light on the
mechanisms involved and revise the roles
of seemingly established ‘‘marker genes’’
in this context.
The first key observation made is that
cell fate following BMP4 stimulation of
hESCs is critically modulated by the pres-
ence or absence of fibroblast growth
factor 2 (FGF2). FGF2 is included in virtu-
ally all hESC media and serves, at least in
part, to sustain expression of the self-
renewal controlling transcription factor
NANOG (Figure 1A; Greber et al., 2010;
Yu et al., 2011). When combining BMP4
and FGF2, however, prominent playersinvolved in mesoderm formation, notably
Brachyury (also known as T), became
strongly induced. Interestingly, the con-
tributing effect by FGF2 in this joint
effort was mediated through NANOG,
as NANOG overexpression in BMP4-
without-FGF2 media caused Brachyury
induction, and NANOG silencing in
BMP4-plus-FGF2 media interfered with
it (Yu et al., 2011). These findings, com-
bined with independent data, support a
revised view of how pluripotency is
controlled. In this model, individual core
transcription factors such as NANOG not
only preserve the undifferentiated state
by activating other ESC-specific genes
and repressing certain lineage inducers.
In addition, they may also actively partici-
pate in promoting differentiation into
specific fates, in collaboration with sig-
naling cues such as BMP in the case of
mesoderm specification (Figures 1A and
1B; Boyer et al., 2005; Loh and Lim, 2011;
Teo et al., 2011; Thomson et al., 2011).
Bernardo et al. also find that the tran-
scription factor CDX2 is required for
mesoderm formation downstream of T,
because CDX2 ablation under BMP4-
plus-FGF2 conditions strongly interfered
with the induction of prominent genes
conferring mesoderm identity (Figure 1B).
This is a surprising and important find-
ing, given that CDX2 has commonly been
associated with extraembryonic—notll 9, August 5, 2011 ª2011 Elsevier Inc. 91
